Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

TCT Daily: ESTROFA: Late Thrombosis Not Increased in DES Patients: Spanish Registry of Drug‐Eluting Stents Shows STEMI, LAD Artery Lesions, Significant Risk Factors

TCT Daily: ESTROFA: Late Thrombosis Not Increased in DES Patients: Spanish Registry of... The use of drug‐eluting stents was associated with a 1.2% incidence of thrombosis in preliminary results from the ESTROFA registry presented by Jose de la Torre Hernandez, MD, PhD, of the Hospital Universitario Marques de Valdecilla in Santander, Spain. In the registry of DES use at 17 hospitals in Spain, there were 162 reported stent thromboses in 13,500 patients; the majority of thromboses (76) occurred within the first 30 days after implantation ( Figure 1 ). 1 The incidence of thrombosis within the first 6 months was 0.82%, approximately the same incidence as with bare‐metal stents, Hernandez said. The incidence of thrombosis more than 6 months after implantation was 0.4%, which is higher than that for bare‐metal stents during the same time period. The registry comprised patients who received a paclitaxel‐eluting stent (60%) or a sirolimus‐eluting stent (40%). There was no significant difference in the incidence of thrombosis between the two stents. Risk factors for thrombosis included acute coronary syndromes (P < 0.0001), ST‐elevation myocordial infarction (MI) (P < 0.0001), lesion of the left anterior descending artery (P < 0.0001), and total occlusion (P = 0.0005). Additional predictors for stent thromboses included renal insufficiency, vessels less than 2.5 mm in diameter, and stent length. Half of the patients in the registry had a lesion of the LAD coronary artery, and 1.7% of these patients had a thrombosis. Twelve percent of patients had ST‐elevation MI, 3.8% of whom experienced thrombosis. Eight hundred patients (6%) had both ST‐elevation MI and a lesion of the LAD coronary artery; the incidence of thrombosis was 5.6% in these patients. The incidence of thrombosis in patients without ST‐elevation MI was 0.8%. Antiplatelet therapy was a significant factor in preventing long‐term thrombosis. Thrombosis rates were significantly lower in patients who were taking aspirin and clopidogrel vs. those taking aspirin alone and those not taking any medication. The incidence of death following an acute or subacute thrombosis was 11.4%, comparable with the rate of death in late thromboses (15%). The rate of rethrombosis was 5.2% following acute or subacute thrombosis and 4.5% following late thrombosis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

TCT Daily: ESTROFA: Late Thrombosis Not Increased in DES Patients: Spanish Registry of Drug‐Eluting Stents Shows STEMI, LAD Artery Lesions, Significant Risk Factors

Journal of Interventional Cardiology , Volume 20 (1) – Feb 1, 2007
Download PDF
1 page

Loading next page...
 
/lp/wiley/tct-daily-estrofa-late-thrombosis-not-increased-in-des-patients-TNxFduxxfN

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
Copyright © 2007 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2007.00231.x
pmid
17300396
Publisher site
See Article on Publisher Site

Abstract

The use of drug‐eluting stents was associated with a 1.2% incidence of thrombosis in preliminary results from the ESTROFA registry presented by Jose de la Torre Hernandez, MD, PhD, of the Hospital Universitario Marques de Valdecilla in Santander, Spain. In the registry of DES use at 17 hospitals in Spain, there were 162 reported stent thromboses in 13,500 patients; the majority of thromboses (76) occurred within the first 30 days after implantation ( Figure 1 ). 1 The incidence of thrombosis within the first 6 months was 0.82%, approximately the same incidence as with bare‐metal stents, Hernandez said. The incidence of thrombosis more than 6 months after implantation was 0.4%, which is higher than that for bare‐metal stents during the same time period. The registry comprised patients who received a paclitaxel‐eluting stent (60%) or a sirolimus‐eluting stent (40%). There was no significant difference in the incidence of thrombosis between the two stents. Risk factors for thrombosis included acute coronary syndromes (P < 0.0001), ST‐elevation myocordial infarction (MI) (P < 0.0001), lesion of the left anterior descending artery (P < 0.0001), and total occlusion (P = 0.0005). Additional predictors for stent thromboses included renal insufficiency, vessels less than 2.5 mm in diameter, and stent length. Half of the patients in the registry had a lesion of the LAD coronary artery, and 1.7% of these patients had a thrombosis. Twelve percent of patients had ST‐elevation MI, 3.8% of whom experienced thrombosis. Eight hundred patients (6%) had both ST‐elevation MI and a lesion of the LAD coronary artery; the incidence of thrombosis was 5.6% in these patients. The incidence of thrombosis in patients without ST‐elevation MI was 0.8%. Antiplatelet therapy was a significant factor in preventing long‐term thrombosis. Thrombosis rates were significantly lower in patients who were taking aspirin and clopidogrel vs. those taking aspirin alone and those not taking any medication. The incidence of death following an acute or subacute thrombosis was 11.4%, comparable with the rate of death in late thromboses (15%). The rate of rethrombosis was 5.2% following acute or subacute thrombosis and 4.5% following late thrombosis.

Journal

Journal of Interventional Cardiology – Wiley

Published: Feb 1, 2007

There are no references for this article.